Lastly, LKB1 mutations are found simultaneously with KRAS mutation in about 10% of NSCLC and seems to confer susceptibility to phenformin, a mitochondrial inhibitor and analogue of the antidiabetic drug metformin. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.